{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Levy DT"],"funding":["Cancer Research UK","Medical Research Council","National Institute for Health Research (NIHR)","Division of Cancer Prevention, National Cancer Institute","NCI NIH HHS"],"pagination":["1196-1211"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9364758"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["116(5)"],"pubmed_abstract":["<h4>Background and aims</h4>Whereas the use of nicotine vaping products (NVPs) is widespread, their impact on smoking prevalence is controversial. This study considered the potential impact of NVPs on smoking prevalence in England.<h4>Design</h4>Indirect simulation model. The England SimSmoke model is validated through 2012, before NVP use became more widely used by smokers. Because information on NVP-related transitions is limited, an indirect method is used; the difference in observed smoking prevalence (reflecting NVPs) is compared with a 2012-2019 counterfactual No-NVP scenario (without NVPs) to estimate the impact of NVPs on smoking and smoking-attributable deaths.<h4>Setting</h4>England, 2000-2019.<h4>Participants</h4>Nationally representative sample of population.<h4>Measurements</h"],"journal":["Addiction (Abingdon, England)"],"pubmed_title":["England SimSmoke: the impact of nicotine vaping on smoking prevalence and smoking-attributable deaths in England."],"pmcid":["PMC9364758"],"funding_grant_id":["P01 CA200512","NIHR200262","P01CA200512","C1417/A14135","MR/S037519/1","22962"],"pubmed_authors":["Jarvis MJ","Li Y","Travis N","Brown J","Levy DT","Yuan Z","McNeill A","Sanchez-Romero LM"],"additional_accession":[]},"is_claimable":false,"name":"England SimSmoke: the impact of nicotine vaping on smoking prevalence and smoking-attributable deaths in England.","description":"<h4>Background and aims</h4>Whereas the use of nicotine vaping products (NVPs) is widespread, their impact on smoking prevalence is controversial. This study considered the potential impact of NVPs on smoking prevalence in England.<h4>Design</h4>Indirect simulation model. The England SimSmoke model is validated through 2012, before NVP use became more widely used by smokers. Because information on NVP-related transitions is limited, an indirect method is used; the difference in observed smoking prevalence (reflecting NVPs) is compared with a 2012-2019 counterfactual No-NVP scenario (without NVPs) to estimate the impact of NVPs on smoking and smoking-attributable deaths.<h4>Setting</h4>England, 2000-2019.<h4>Participants</h4>Nationally representative sample of population.<h4>Measurements</h","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-18T15:25:39.208Z","creation":"2025-04-07T02:02:21.136Z"},"accession":"S-EPMC9364758","cross_references":{"pubmed":["32949419"],"doi":["10.1111/add.15269"]}}